Valuation: Ind-Swift Laboratories Limited

Market Cap 35.64B 374M 335M 309M 280M 523M 532M 3.69B 1.47B 18.65B 1.4B 1.37B 59.07B P/E 2025
2.38x
P/E 2026 26.1x
Enterprise Value 31.42B 330M 296M 273M 247M 461M 469M 3.25B 1.3B 16.45B 1.24B 1.21B 52.09B EV / Sales 2025
0.12x
EV / Sales 2026 1.11x
Free-Float
32.35%
Yield 2025 *
-
Yield 2026 -
1 day+8.14%
1 week+18.66%
Current month+5.41%
1 month-0.80%
3 months+83.29%
6 months+201.12%
Current year+364.89%
1 week 316
Extreme 316
425
1 month 316
Extreme 316
425
Current year 87.25
Extreme 87.25
425
1 year 87.15
Extreme 87.15
425
3 years 68.72
Extreme 68.72
425
5 years 52.65
Extreme 52.65
425
10 years 15
Extreme 15
425
Manager TitleAgeSince
Chief Executive Officer 46 -
Chief Executive Officer 44 15/06/2011
Director of Finance/CFO - 29/09/2018
Director TitleAgeSince
Director/Board Member 44 -
Chairman 74 -
Director/Board Member 35 23/03/2010
Date Insider Type Main position Quantity % Market Cap. Importance
12/09/24 Sell

Chief Financial Officer

30,000 0.0508%
Change 5-day change 1-year change 3-year change Capi.($)
+8.14%+18.66%+297.75%+380.14% 346M
+6.63%+5.13%+68.86%+145.20% 1,148B
+1.53%+2.84%+47.48%+89.01% 652B
+1.68%+1.96%+29.16%+109.31% 505B
+0.73%+2.45%+54.26%+68.96% 384B
+3.83%-0.62%+69.01%+42.32% 348B
+2.38%+2.65%+34.31%+57.95% 294B
+2.26%+0.55%+3.92%+28.92% 264B
+1.97%+3.01%+57.91%+76.14% 244B
+4.03%+5.36%+39.76%+116.14% 197B
Average +2.92%+3.24%+70.24%+111.41% 403.75B
Weighted average by Cap. +2.25%+2.89%+50.24%+95.99%

Financials

2025 2026
Net sales 5.62B 58.99M 52.83M 48.74M 44.11M 82.48M 83.81M 582M 232M 2.94B 221M 217M 9.31B 6.49B 68.17M 61.06M 56.33M 50.97M 95.32M 96.86M 672M 268M 3.4B 256M 250M 10.76B
Net income 2.5B 26.3M 23.56M 21.74M 19.67M 36.78M 37.37M 259M 103M 1.31B 98.71M 96.61M 4.15B 431M 4.53M 4.06M 3.74M 3.39M 6.33M 6.43M 44.65M 17.81M 226M 17M 16.63M 715M
Net Debt -4.27B -44.79M -40.12M -37.01M -33.49M -62.63M -63.65M -442M -176M -2.23B -168M -165M -7.07B -4.21B -44.24M -39.62M -36.55M -33.08M -61.86M -62.85M -436M -174M -2.2B -166M -162M -6.98B
Projected Income Statement - Annual - Ind-Swift Laboratories Limited
Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,388
Date Price Change Volume
29/10/26 ₹409.80 +8.14% 3,539,164
28/10/26 ₹378.95 +2.75% 589,736
27/10/26 ₹368.80 +9.42% 850,817
26/10/26 ₹337.05 +2.93% 414,766
23/10/26 ₹327.45 -5.18% 658,248
  1. Stock Market
  2. Stocks
  3. INDSWFTLAB Stock